Founded in 2019 by a team of entrepreneurs and surgeons from Washington University in St. Louis, Caeli

Vascular Inc., has developed the SUMMIT™ Multi-Modal technology platform for the treatment of thrombotic disease. SUMMIT™'s patented therapeutic bundle is both comprehensive and transformative and establishes a new paradigm for the treatment of multiple thrombotic diseases. 

Caeli Vascular's SHIELD™ Thrombectomy System is the first product developed on this platform and will target large volume Deep Vein Thrombosis (DVT). SHIELD™ is designed to provide better patient outcomes in a single device/single session setting to dramatically reduce device utilization, lower costs and increase profitability to healthcare institutions.